ArticleCureus2025
Effectiveness of Daily Teriparatide in Managing Glucocorticoid-Induced Osteoporosis in Rheumatic Disease Patients After Switching From Bisphosphonate Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis is a serious complication of systemic glucocorticoid therapy. Bisphosphonates are commonly used to treat glucocorticoid-induced osteoporosis (GIOP) but may be ineffective. Teriparatide, a recombinant form of parathyroid hormone, stimulates bone formation and may be a promising alternative for patients who show an inadequate response to bisphosphonates. Nonetheless, evidence supporting the effectiveness of daily teriparatide in GIOP patients with an inadequate bisphosphonate response remains limited. Serum soluble receptor activator of nuclear factor-kappa B ligand (sRANKL) and osteoprotegerin (OPG) are important biomarkers of bone metabolism and may aid in understanding and treating various diseases. However, changes in serum sRANKL and OPG levels following the administration of teriparatide to GIOP patients remain unclear. Therefore, the present study investigated the effects of daily teriparatide on bone mineral density (BMD) and the biochemical markers of bone metabolism in rheumatic disease patients with GIOP.
methodsThis study included 23 patients with GIOP in rheumatic diseases. Patients were switched from oral bisphosphonates to daily teriparatide. Patients receiving a median daily dose of 5.0 mg of prednisolone were eligible for the present study. BMD at the lumbar spine was assessed before and six months after teriparatide therapy. Serum sRANKL, OPG, bone formation markers (bone alkaline phosphatase, osteocalcin, and procollagen type 1 N-terminal peptide), and bone resorption markers (crosslinked N-telopeptide of type I collagen and tartrate-resistant acid phosphatase isoform 5b) were measured during teriparatide therapy.
resultsSix months of treatment with teriparatide significantly increased lumbar spine BMD (before treatment 0.67 [0.60-0.74] and six months after treatment (0.71 {0.67-0.81} {median and interquartile range} g/cm2, p = 0.0337). Serum sRANKL levels significantly decreased after teriparatide therapy (0.07 {0.00-0.19} to 0.00 {0.00-0.07} pmol/L, p = 0.0182), while OPG levels remained unchanged (6.71 {5.79-8.13} to 7.18 {5.96-8.92} pmol/L, p = 0.588). The sRANKL/OPG ratio significantly decreased from baseline (0.62 {0.00-3.08}) to after teriparatide therapy (0.00 {0.00-0.11}, p = 0.0287). All serum bone formation markers and bone resorption markers increased after teriparatide therapy. No new vertebral fractures were detected.
conclusionsSwitching from bisphosphonates to daily teriparatide significantly increased lumbar spine BMD in rheumatic disease patients with GIOP. Sequential therapy with daily teriparatide after bisphosphonates may be an effective treatment for GIOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.